Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 140.18M P/E - EPS this Y 51.00% Ern Qtrly Grth -
Income -94.95M Forward P/E -7.69 EPS next Y 62.10% 50D Avg Chg -38.00%
Sales 84.48M PEG - EPS past 5Y - 200D Avg Chg -55.00%
Dividend N/A Price/Book 4.73 EPS next 5Y - 52W High Chg -74.00%
Recommedations 1.70 Quick Ratio 1.08 Shares Outstanding 46.73M 52W Low Chg 17.00%
Insider Own 0.03% ROA -25.81% Shares Float 34.17M Beta -
Inst Own 12.87% ROE -295.96% Shares Shorted/Prior 2.36M/2.48M Price 3.00
Gross Margin 51.43% Profit Margin -112.40% Avg. Volume 1,246,671 Target Price 18.44
Oper. Margin -90.44% Earnings Date Nov 30 Volume 516,617 Change 5.26%
Redhill Biopharma Ltd. News
11/24/21 RedHill Biopharma to Host Third Quarter 2021 Financial Results and Operational Highlights Webcast on November 30, 2021
11/23/21 RedHill Biopharma Announces Closing of $15.5 Million Public Offering of American Depositary Shares
11/19/21 Mid-Afternoon Market Update: Dow Falls 200 Points; Connect Biopharma Shares Tumble
11/19/21 Mid-Day Market Update: Crude Oil Down Over 4%; UWM Holdings Shares Surge
11/19/21 RedHill Biopharma Announces Pricing of $15.5 Million Public Offering of American Depositary Shares
11/18/21 RedHill Biopharma Announces Underwritten Public Offering of American Depositary Shares
11/16/21 When Can We Expect A Profit From RedHill Biopharma Ltd. (NASDAQ:RDHL)?
11/15/21 RedHill Biopharma Ltd Announces RedHill: LPI in Part A of RHB-107 P2/3 COVID Study
11/15/21 RedHill Biopharma Announces Last Patient Randomized in Part A of Ongoing Phase 2/3 COVID-19 Study of Once-Daily Oral RHB-107 in Non-Hospitalized Patients
11/09/21 RedHill Biopharma to Present at H.C. Wainwright 7th Annual Israel Conference and German Equity Forum (EKF) 2021
11/08/21 RedHill Biopharma and South Korea's Kukbo Co. Announce a Strategic Investment of Up To $10 Million in RedHill
11/01/21 11 Best Covid Vaccine and Pill Stocks To Invest In
10/25/21 RedHill Biopharma Presents New Talicia(R) and Movantik(R) Data Analyses at ACG 2021
10/22/21 Why BioNTech and RedHill Are Soaring This Week, While Novavax Is Sinking
10/20/21 RedHill Biopharma to Present at the BIO-Europe 2021 Conference
10/19/21 David v Goliath in The Race to Develop an Oral Therapy for COVID-19
10/18/21 RedHill Biopharma Announces Insider Buying
10/12/21 RedHill Biopharma Ltd Announces New U.S. Patent for RedHill's Talicia for H.pylori
10/12/21 RedHill Biopharma Announces New U.S. Patent Covering Talicia for H. pylori Infection Through 2034

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 1/2a study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and Phase 2a study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; and RHB-106, an encapsulated formulation for bowel preparation, which has completed Phase 2a study. The company was incorporated in 2009 and is headquartered in Tel Aviv, Israel.

RDHL Chatroom

User Image Cinderella74 Posted - 3 hours ago


User Image QuoVadisShare Posted - 4 hours ago

$RDHL Of course they need money, which is actually relatively normal - IF - the money is used in an innovative and future-oriented way. Expansion of production - sales etc. Obviously that would be the best case. They don't have a billionaire like (Heidelberg Pharma) who gives the company millions every year

User Image Bullrun1971 Posted - 4 hours ago

$RDHL I’m still confused and concerned as to why they did another offering AFTER insider buying and Kukbo deal? Cash flow problems?

User Image QuoVadisShare Posted - 6 hours ago

$RDHL Redhill has good, very good candidates who can at least reduce this pandemic / diseases. Management should now do everything in its power to accelerate the steps involved in the various approval procedures. But this does not only apply to Covid drugs. The train is now approaching Redhill very slowly - Redhill could jump up and the journey begins. If not now then when ? If everything goes well, there could be a second BioNTech here. Now it will really show whether the management is clever enough and also gives us invested information. November 30, 2021 will also point the way - not for drugs but for transparency towards us.

User Image stocktowatch7 Posted - 14 hours ago

$RDHL, $PLG here goes on http://www.stocksequity.com/active-stocks/is-this-just-a-random-move-redhill-biopharma-ltd-nasdaqrdhl-platinum-group-metals-ltd-amexplg/

User Image MM1968 Posted - 20 hours ago

$RDHL I’m not in this for COVID. If RHB-104 ever gets approved, we go to triple digits.

User Image Cinderella74 Posted - 22 hours ago

$RDHL last chance to rdhl… but it could be a home run.

User Image WolfofBanune Posted - 22 hours ago

$RDHL positive invitro test results vs B1.1.529 needed for Opaganib and Upamostat shortly! Would speed up everything!

User Image bucodolores Posted - 22 hours ago

$PTN I'm curious if $RDHL will move up a bit from getting slammed this week. Would be nice.

User Image xxtpat Posted - 22 hours ago

$RDHL The pandemic always has surprises in store. Bad for the world, but there are a few opportunities for Redhill right now.

User Image WolfofBanune Posted - 22 hours ago

$RDHL crazy how lucky rdhl is for this situation. PFE would be up double digits in todays situation. But they would highlight every edge of that.

User Image Wynn77 Posted - 22 hours ago

$RDHL Up 5.26% in a market down 900pts. We will take it!

User Image Irishbroker17 Posted - 1 day ago

$RDHL bought a few here.

User Image Jac1962 Posted - 1 day ago

$RDHL That's with sickly people 62%.....

User Image Jac1962 Posted - 1 day ago

$RDHL Opaganib 62% effective Merck 30%.....

User Image tickeron Posted - 1 day ago

Does this make you nervous? $RDHL in -3.89% Downtrend, sliding for three consecutive days on November 23, 2021. View odds for this and other indicators: https://srnk.us/go/3190104

User Image RealDill Posted - 1 day ago

$RDHL Israel has reported a infection by the nu variant. Sure wish this was an Israeli company… oh, that’s right, they are an Israeli company!

User Image Bullrun1971 Posted - 1 day ago

$RDHL green to REDhill …its in the name and the fucking logo

User Image JaythePa Posted - 1 day ago

$RDHL if RedHill would partner with a big Pharma you would see things moving a lot faster but you all know that

User Image 4vip Posted - 1 day ago


User Image RealDill Posted - 1 day ago

$RDHL last week reported last enrollee in Upamostat part A trial. so I guess 28 days from that date the data should be complete, right?

User Image RealDill Posted - 1 day ago

$RDHL https://www.reuters.com/business/healthcare-pharmaceuticals/merck-says-covid-19-pill-cuts-hospitalization-death-risk-by-30-2021-11-26/

User Image vk04982 Posted - 1 day ago

$RDHL One of the very few pharma companies already testing in South Africa! Wonder what the future unfolds....

User Image Jac1962 Posted - 1 day ago

$RDHL REDHILL is testing in South Africa.....

User Image Bullrun1971 Posted - 1 day ago

$RDHL sounds shit to me plus it’s expensive and dangerous!? Merck and partner Ridgeback Biotherapeutics said their COVID-19 antiviral molnupiravir reduced the risk of hospitalization or death in at-risk adults with mild-to-moderate COVID to 6.8% from 9.7% in the placebo group in the latest update of data from its study dubbed MOVe-OUT. That is equal to an absolute risk reduction of 3.0% and a relative risk reduction of 30%.

User Image RealSamHouston Posted - 1 day ago

$RDHL btw pfizer and merck claim efficacy against variants...

User Image tothemooninjune Posted - 1 day ago

$RDHL it is as if destiny doesnt want to stop giving them „one more chance“ to turn around their fate. It is insane

User Image WolfofBanune Posted - 1 day ago

$RDHL good news on tuesday would be perfect moment. Didn‘t think covid situation would become that worse so fast and opaganib was overdue, but with new variant this is needed more than ever!

User Image WolfofBanune Posted - 1 day ago

$RDHL today would be a great day to promote Opaganib is working on all variants.

User Image katscreen Posted - 1 day ago

$RDHL Never has there been more need for an alternate medication like Opaganib that works for more severe Covid infections. The NU variant emerging in South Africa is heavily mutated and vaccines are allegedly only 30% effective against this strain. Unlike the Pfizer and Merck pills, Opaganib also addresses the Cytokine storm in moderately severe Covid cases.

Analyst Ratings
HC Wainwright & Co. Buy Sep 15, 21
Cantor Fitzgerald Overweight Aug 31, 21
WBB Securities Buy May 28, 21
HC Wainwright & Co. Buy May 18, 21
BTIG Buy Sep 11, 20
H.C. Wainwright Buy Mar 5, 20
WBB Securities Strong Buy Jul 12, 19
WBB Securities Buy Mar 12, 19
Ladenburg Thalmann Buy Jun 25, 18